Astellas puts forward board nominees in OSI bid
This article was originally published in Scrip
Astellas has now drawn up a full set of independent directors for nomination for election at the upcoming annual general meeting of its acquisition target OSI Pharmaceuticals.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.